Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

First Edition

Review Article March 25 2025
Metabolic Pathways in Deep Vein Thrombosis: A New Frontier for Therapeutic Intervention
Research Article March 24 2025
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results
Research Article March 20 2025
Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes
Research Article March 19 2025
NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma
Brief Report March 16 2025
The neutrophil antigen 3a/b polymorphism in SLC44A2 unexpectedly encodes Csa/Csb red cell antigens
Discussion March 16 2025
Proteostasis Disruption in Inherited Bone Marrow Failure Syndromes
Discussion March 16 2025
Pathogenesis of Paroxysmal Nocturnal Hemoglobinuria
Review Article March 16 2025
Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics
Research Article March 16 2025
Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study
Research Article March 16 2025
Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China
Research Article March 16 2025
Loss of BCL7A Permits IRF4 Transcriptional Activity and Cellular Growth in Multiple Myeloma
Research Article March 16 2025
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma
Research Article March 16 2025
Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement
Research Article March 12 2025
Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q+
Research Article March 12 2025
Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma
Research Article March 12 2025
A Controlled Trial for Preventing Priapism in Sickle Cell Anemia: Hydroxyurea plus Placebo vs Hydroxyurea plus Tadalafil
Review Article February 28 2025
Exploring the thrombus niche: Lessons learned and potential therapeutic opportunities
Review Article February 28 2025
The Future of Follicular Lymphoma Management: Strategies on the Horizon
Review Article February 28 2025
End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?
Research Article February 26 2025
Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma
Research Article February 26 2025
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study
Review Article January 27 2025
Platelet activation and signaling in thrombus formation
Review Article January 27 2025
Factor XIII: Driving (Cross-)Links in Hemostasis, Thrombosis, and Disease
Review Article January 27 2025
Frontline treatment of follicular lymphoma: What will it take to change current practice?
Research Article January 22 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial
Page 3 of 3

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals